Healthcare Services

A significant industry trend in the Endocrine Testing Market includes the Point-Of-Care NT-Probnp Test For Cardiovascular Risk Screening In Diabetic Patients

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Endocrine Testing Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The endocrine testing market has experienced robust growth in recent years. It is projected to expand from $2.79 billion in 2025 to $3.05 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. The historical growth can be attributed to several factors including diabetes prevalence, thyroid disorder incidence, the expansion of clinical laboratories, increased hormone testing awareness, and the growth of chronic disease diagnostics.

The endocrine testing market size is anticipated to undergo significant expansion in the coming years. By 2030, it is projected to attain a value of $4.15 billion, advancing at a compound annual growth rate (CAGR) of 7.9%. This expected growth within the forecast period can be linked to a heightened emphasis on preventive healthcare, personalized treatment planning, the automation of hormone testing processes, the increasing number of diagnostic centers, and the implementation of endocrine disease screening programs. Noteworthy trends for this period include the rising occurrence of hormonal disorders, a greater embrace of comprehensive hormone panels, the broadening of preventive endocrine screening initiatives, an escalating need for accurate diagnostic results, and the incorporation of advanced diagnostic technologies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15562&type=smp

What Key Drivers Are Influencing The Growth Of The Endocrine Testing Market?

The increasing incidence of diabetes is projected to drive the expansion of the endocrine testing market in the future. Diabetes encompasses a variety of conditions characterized by elevated blood sugar (glucose) levels. The increase in diabetes cases stems from factors such as poor dietary habits, inactive lifestyles, genetic predispositions, and an aging demographic. Endocrine tests, such as hemoglobin A1c, fasting plasma glucose, and C-peptide tests, are employed in managing diabetes for diagnosis, tracking glucose levels, and evaluating insulin generation and responsiveness. For instance, in June 2024, data from the National Health Service (NHS), a UK-based government department, indicated a rise in cases among individuals under 40, from 173,166 in 2022 to 216,440 in 2023. This notable increase signifies a troubling pattern within this particular age group. The statistics illustrate a swift surge in diabetes prevalence among younger demographics. Consequently, the growing occurrence of diabetes is fueling the endocrine testing market.

What Major Segment Divisions Exist Within The Endocrine Testing Market?

The endocrine testing market covered in this report is segmented –

1) By Test Type: Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Other Types

2) By Technology: Tandem Mass Spectrometry, Immunoassay, Monoclonal And Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Diagnostic Centers, Other End-Users

Subsegments:

1) By Estradiol (E2) Test: Serum Estradiol Test, Urinary Estradiol Test

2) By Follicle Stimulating Hormone (FSH) Test: FSH Serum Test, FSH Urine Test

3) By Human Chorionic Gonadotropin (hCG) Hormone Test: Quantitative hCG Test, Qualitative hCG Test

4) By Luteinizing Hormone (LH) Test: LH Serum Test, LH Urine Test

5) By Dehydroepiandrosterone Sulfate (DHEAS) Test: Serum DHEAS Test, Saliva DHEAS Test

6) By Progesterone Test: Serum Progesterone Test, Urinary Progesterone Test

7) By Testosterone Test: Free Testosterone Test, Total Testosterone Test

8) By Thyroid Stimulating Hormone (TSH) Test: TSH Serum Test, TSH Saliva Test

9) By Prolactin Test: Serum Prolactin Test, Plasma Prolactin Test

10) By Other Types: Cortisol Test, Insulin Test, Growth Hormone (GH) Test, Aldosterone Test

What Key Developments And Trends Are Impacting The Endocrine Testing Market?

Leading companies active in the endocrine testing market are developing point-of-care testing solutions to boost the accessibility and efficiency of diagnosing endocrine disorders. Point-of-care testing offers quick results, which can aid in the rapid diagnosis and management of heart failure in patients presenting with symptoms such as shortness of breath and fatigue. For example, in April 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, launched a point-of-care NT-proBNP test in India, specifically designed for screening diabetes patients at risk of cardiovascular diseases, including heart failure (HF). This test facilitates early detection and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions, ultimately fostering improved outcomes and patient well-being.

Which Companies Are Leading Innovation In The Endocrine Testing Market?

Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.

Read the full endocrine testing market report here:

https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Endocrine Testing Market?

North America was the largest region in the endocrine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Endocrine Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15562&type=smp

Browse Through More Reports Similar to the Global Endocrine Testing Market 2026, By The Business Research Company

Endocrine Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report

Thyroid Function Test Global Market Report

https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report

Peptide Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795